SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc is trending after its CFO and General Counsel abruptly departed amidst an ongoing SEC accounting probe, invalidated financial disclosures, and significantly lowered guidance, triggering a massive stock sell-off. While many in the community express serious concerns about the company's financial integrity and long-term outlook, others view the steep decline as an overreaction and a potential opportunity for a bounce.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

REGENXBIO is trending as the FDA issued a Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing concerns with trial design and the use of natural history controls. This decision has sparked widespread community discussion regarding the financial outlook for RGNX and the potential impact on its other gene therapy candidates, which utilize similar trial methodologies.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing heavy discussion and a sharp sell-off following its recent earnings, which delivered mixed results and conservative guidance that many in the community view as an extreme overreaction given the company's profitability and AI-powered model. This severe market reaction, fueled by broader negative sentiment impacting the fintech sector, has sparked intense debate between those accumulating at what they see as deeply undervalued levels and others frustrated by alleged market manipulation.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is experiencing a sharp rebound, driven by renewed analyst confidence in robust AI server CPU demand and strategic leadership additions sparking major partnership speculation. While some in the community eye this as a significant buying opportunity, others remain wary of a 'dead cat bounce' following its post-earnings volatility.

Ichor Holdings Ltd. engages in designing, engineering, and manufacturing fluid delivery subsystems for semiconductor capital equipment. It offers gas and chemical delivery systems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The firm also manufactures precision machined components, weldments, and proprietary products for use in fluid delivery systems for direct sales to its customers. The company was founded in 1999 and is headquartered in Fremont, CA.

Ichor Holdings Ltd

Ichor Holdings is experiencing a notable after-hours surge following a strong earnings report that surpassed expectations and provided an optimistic outlook. Community sentiment is highly bullish, fueled by both the positive financial results and speculative interest from reported political insider buying, emphasizing ICHR's role in the semiconductor capital equipment sector amidst a focus on domestic chip manufacturing.

GALA is designed to power the Gala Games ecosystem to support gaming re-imagined to benefit creators and players, alike.

Gala Games

Gala Games (GALA) is generating buzz due to new ecosystem developments, including strategic partnerships for NFT gaming in China and expanded multi-chain integrations, fueling optimism for its Web3 entertainment platform. However, the community remains sharply divided, with ongoing debates concerning its long-term potential versus past performance and perceived token distribution pressures.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is drawing significant market attention as it reports strong earnings with increased deliveries and positive cash flow, buoyed by major new aircraft orders from India, while investors closely monitor its production ramp-up and ongoing regulatory certifications.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is trending after its NASDAQ debut was swiftly followed by a significant equity raise and reverse stock split, sparking a fierce debate among investors over immediate dilution versus the long-term funding for its potentially "revolutionary" muscle regeneration drug for Duchenne Muscular Dystrophy.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending ahead of its Q4 earnings report, with community discussion focused on its strategic hyperscaler contracts and full-stack AI infrastructure positioning amid an industry-wide surge in AI spending. Bullish investors are anticipating strong results and long-term growth, while some express caution regarding potential market volatility and profitability concerns.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to anticipation surrounding its upcoming Q4 earnings, where investors are keen to see the impact of recent subscription price hikes and new content pushes like AI-powered playlists and music videos. The community is actively discussing potential customer churn versus increased profitability, compounded by recent analyst upgrades and reports of a major content catalog leak.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$207B Market Shift: The Race for Fast Track Approval in Oncology

$207B Market Shift: The Race for Fast Track Approval in Oncology $207B Market Shift: The Race for Fast Track Approval in Oncology PR Newswire VANCOUVER, BC, Feb. 5, 2026 Issued on behalf of...

<ul class="summary-bullets"><li>The company said that the designation is supported by clinical data which demonstrates a 33% objective response rate for pelareorep-based therapy.&nbsp;</li><li>According to Oncolytics, there are an estimated 2 million new colorectal cancer cases each year globally.</li><li>Pelareorep now has Fast Track Designation for two gastrointestinal cancers including pancreatic cancer.</li></ul><p>Shares of Oncolytics Biotech Inc. (ONCY) rallied 8% at the time of writing ON Wednesday after the company announced that the U.S. Food and Drug Administration has granted a fast track designation to its cancer drug pelareorep in combination with other drugs.</p><p>The agency granted the designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for the treatment of certain patients with metastatic colorectal cancer for whom few effective treatment options exist.</p><h2 class="st-heading-2">Why The Designation?</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/04/3232074/0/en/Oncolytics-Biotech-Receives-FDA-Fast-Track-Designation-for-Pelareorep-in-2L-KRAS-Mutant-MSS-Metastatic-Colorectal-Cancer.html">said</a> that the designation is supported by clinical data which demonstrates a 33% objective response rate for pelareorep-based therapy compared to approximately 10% ORR with standard-of-care in the particular patient population.</p><p>According to Oncolytics, there are an estimated 2 million new colorectal cancer cases each year globally, with an annual total addressable market of approximately $3-5 billion for the subgroup it targets.</p><h2 class="st-heading-2">Plans Ahead</h2><p>The company now intends to initiate a controlled clinical study in the subgroup comparing standard-of-care therapy alone versus standard-of-care plus pelareorep.</p><p>The first clinical site, it noted, is expected to be activated in March, with up to 10 additional sites expected to open shortly thereafter. Interim data from the study are expected by year-end, it added.</p><h2 class="st-heading-2">Perks Of The Designation</h2><p>The Fast Track Designation enables more frequent meetings and communication with the regulator to ensure alignment on development plans and the collection of clinical data needed to support approval. Programs with Fast Track Designation may also be eligible for accelerated approval and priority review if certain criteria are met.</p><p>Pelareorep now has Fast Track Designation for two gastrointestinal cancers including pancreatic cancer. The company is also studying the drug in metastatic breast cancer.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around ONCY stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.</p><p>A Stocktwits user highlighted high price targets on the stock.</p><p><stembedurl>https://www.stocktwits.com/sk7777777/message/643949165</stembedurl></p><p>According to data from Koyfin, of the seven analysts covering the stock, six have a ‘buy’ or higher rating on the shares of the company while one rates it ‘hold’.</p><p>The stock has an average price target of $5.49, representing a potential upside of over 400% from current trading levels.</p><p><a href="https://stocktwits.com/symbol/ONCY">ONCY stock</a> has gained 32% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ionq-stock-tumbles-as-wolfpack-reveals-short-position/cZbj44zR4NP">IONQ Stock Tumbles 10% As Wolfpack Reveals Short Position</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug

The agency granted the designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for the treatment of certain patients with metastatic colorectal cancer. 

Equity

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium PR Newswire VANCOUVER, BC, Jan...

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks PR Newswire VANCOUVER, BC, Jan. 27, 2026...

Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Purchases 100,000 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director Bernd Seizinger bought 100,000 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was bought at an...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock...

Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Acquires 100,000 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director Bernd Seizinger purchased 100,000 shares of the company's stock in a transaction on Friday, January 16th. The stock was acquired at an...

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff PR Newswire VANCOUVER, BC, Jan...

Smart Oncology: 5 Stocks Chasing the $317B Prize

Smart Oncology: 5 Stocks Chasing the $317B Prize Smart Oncology: 5 Stocks Chasing the $317B Prize PR Newswire VANCOUVER, BC, Dec. 31, 2025 Issued on behalf of Oncolytics Biotech Inc...

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech, Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

ONCY
Oncolytics Biotech, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ONCY News

ONCYOncolytics Biotech, Inc.